PolyPid ( ($PYPD) ) has shared an announcement. PolyPid Ltd. announced its third-quarter 2025 financial results and provided a corporate update, ...
- Rare disease commercial veteran Mr. Grabow to lead Immix’s U.S. launch and commercial buildout for NXC-201 in relapsed/refractory AL Amyloidosis, a serious, rare, blood disease with no currently ...
Rugiet, which offers ED meds that work on both brain chemistry and blood flow, is attempting to change up the messaging around ED with plenty of double entendres to break the awkward ice. The brand’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback